Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors by Yusuke Hamakawa, Ayumi Hirahara, Akiko Hayashi, Kota Ito, Hiroyuki Shinohara, Aya Shiba, Yuko Higashi, Masaharu Aga, Kazuhito Miyazaki, Yuri Taniguchi, Yuki Misumi, Yoko Agemi, Yukiko Nakamura, Tsuneo Shimokawa, Hiroaki Okamoto

Subjects: Get full text

Exploring the role of metabolic pathways in TNBC immunotherapy: insights from single-cell and spatial transcriptomics by Shi-liang Chen, Yi-Ran Fei, Yi-Ran Fei, Xin-xian Cai, Xin-xian Cai, Cong Wang, Shi-yuan Tong, Zhe-zhong Zhang, Yan-xia Huang, Dan-dan Bian, Yi-bo He, Xiao-xiao Yang

Subjects: Get full text

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors by Yuhui Yang, Yuhui Yang, Yuhui Yang, Pingping Long, Pingping Long, Ying Tuo, Ying Tuo, Xiaoxiao Wang

Subjects: “…immune checkpoint inhibitors…”
Get full text

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunities by Wen-yu Cai, Xin-xian Cai, Yi-ran Fei, Rui Ye, Ding-ming Song, Dan Hu, Wan-wan Zhang, Ming-fei Xia, Xiao-xiao Yang

Subjects: Get full text

Macrophages facilitate tumor cell PD‐L1 expression via an IL‐1β‐centered loop to attenuate immune checkpoint blockade by Cheng Xu, Yu Xia, Bai‐Wei Zhang, Emmanuel Kwateng Drokow, Hua‐Yi Li, Sen Xu, Zhen Wang, Si‐Yuan Wang, Ping Jin, Tian Fang, Xiao‐Ming Xiong, Pu Huang, Ning Jin, Jia‐Hong Tan, Qing Zhong, Yu‐Xin Chen, Qi Zhang, Yong Fang, Fei Ye, Qing‐Lei Gao

Subjects: “…immune checkpoint blockade…”
Get full text

The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classifi... by Liang Zheng, Fang Hu, Wei Nie, Jun Lu, Bo Zhang, Jianlin Xu, Shuyuan Wang, Ying Li, Xiaoxuan Zheng, Wei Zhang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Baohui Han, Hua Zhong, Xueyan Zhang

Subjects: Get full text

Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association by Alexander D. Woods, MD, Katelyn Kim, MD, Anna Axelson, MD

Subjects: Get full text

Editorial: Tertiary lymphoid structures (TLS) in the tumor immune microenvironment by Xinbo Gao, Xiangqin Zhao, Xuesong Li, Jin Zhang, Hui Zhao, Ying Ma

Subjects: Get full text

Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report by Yugo Matsumura, Seiya Ichihara, Kaori Nii, Kazumasa Nanjo, Naoki Kadota, Yoshio Okano, Hisanori Machida, Nobuo Hatakeyama, Hiroyuki Hino, Keishi Naruse, Tsutomu Shinohara, Shoji Sakiyama, Eiji Takeuchi

Subjects: “…immune checkpoint inhibitors…”
Get full text

Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment by Tangyi Wang, Yadian Lei, Jingwei Sun, Li Wang, Yuxin Lin, Zhijing Wu, Shoude Zhang, Chengzhu Cao, Chengzhu Cao, Chengzhu Cao, Haiyan Wang, Haiyan Wang, Haiyan Wang

Subjects: “…immune checkpoint blockade…”
Get full text

CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody by Cristina Melero, S. Jimmy Budiardjo, Anahita Daruwalla, Lance Larrabee, Oleg Ganichkin, Alexander J. Heiler, Jill Fenaux, Ben Chung, Germaine Fuh, Yao-Ming Huang

Subjects: Get full text

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer by Satoshi Endo, Hisao Imai, Atsuto Mouri, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Junichi Nakagawa, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu

Subjects: Get full text

Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors by Zixi Wu, Junbiao Zhang, Le Li, Zhihua Wang, Chunguang Yang

Subjects: Get full text

Impacts of hyperthermic chemotherapeutic agent on cytotoxicity, chemoresistance-related proteins and PD-L1 expression in human gastric cancer cells by Bor-Chyuan Su, Guan-Yu Chen, Chun-Ming Yang, Wei-Ting Chuang, Meng-Chieh Lin, Pei-Ling Hsu, Chu-Wan Lee, Chih-Cheng Cheng, Shih-Ying Wu, Bo-Syong Pan, Hsin-Hsien Yu

Subjects: Get full text

Inhibiting HnRNP L-mediated alternative splicing of EIF4G1 counteracts immune checkpoint blockade resistance in Castration-resistant prostate Cancer by Xumin Zhou, Shilong Cheng, Zhongjie Chen, Jinming Zhang, Jiaqi Wang, Qiang Li, Xumin Zhou

Subjects: Get full text

The effect of baseline versus early glucocorticoid use on immune checkpoint inhibitor efficacy in patients with advanced NSCLC by Yifan Wang, Yifan Wang, Jianying Zhou, Simin Peng, Simin Peng, Zhao Cui, Zhao Cui, Weiqi Wang, Weiqi Wang, Wenqin Zeng, Wenqin Zeng, Tingting Qiu, Zhentian Liu

Subjects: Get full text

Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence by Yuta Yamanaka, Yukiko Okuno, Keisuke Kamisako, Yuta Okazaki, Kentaro Nakanishi, Yume Sanada, Kiyori Yoshida, Tatsuki Ikoma, Yuki Takeyasu, Utae Katsushima, Hiroshige Yoshioka, Takayasu Kurata

Subjects: Get full text

Late-onset and relapsed cytokine release syndrome after nivolumab treatment in a patient with head and neck squamous cell carcinoma: a case report by Tomoyuki Otsuka, Yoshiki Kojitani, Fumio Imamura, Junko Fukutake, Minako Nishio, Takashi Fujii, Toshihiro Kudo

Subjects: “…immune checkpoint inhibitor…”
Get full text

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison by Wei Chen, Wei Chen, Soichiro Yoshida, Noriyoshi Miura, Shohei Fukuda, Hiroshi Fukushima, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii

Subjects: Get full text

PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) by Stefania Angelicola, Francesca Giunchi, Francesca Ruzzi, Mariateresa Frascino, Mary Pitzalis, Laura Scalambra, Maria Sofia Semprini, Olga Maria Pittino, Chiara Cappello, Irene Siracusa, Ilaria Candida Chillico, Martina Di Noia, Cristian Turato, Silvia De Siervi, Francesco Lescai, Teresa Ciavattini, Giulia Lopatriello, Luca Bertoli, Hugo De Jonge, Luisa Iamele, Annalisa Altimari, Elisa Gruppioni, Andrea Ardizzoni, Marzia Rossato, Francesco Gelsomino, Pier-Luigi Lollini, Arianna Palladini

Subjects: Get full text